1 withdrawn. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Recurrent High Grade Endometrioid Adenocarcinoma: new trials by email Literature Review of Recurrent High Grade Endometrioid Adenocarcinoma trials Research Report on Recurrent High Grade Endometrioid Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer Bevacizumab, Biospecimen Collection, Computed Tomography - Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-10-31 | 2025-06-03 |
ASTX-660 (1) · Bevacizumab (1) · Disulfides (1) · Immunoglobulin G (1) · Magnetic Resonance Spectroscopy (1) · Paclitaxel (1) · Specimen Handling (1) · Taxes (1)
National Cancer Institute (NCI) (1)
Kristen P Zeligs (1)
U10CA180868 (1)